The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

BackgroundPulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive disease without standardized treatment strategies. The efficacy of second-line or beyond immune checkpoint inhibitors (ICIs) has been proven in recent studies, whereas the evidence for first-line immunotherapy for PSC is still...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Zhimin Zeng, Xiaoying Qian, Fanrong Liu, Yong Wang, Yong Yuan, Chen Fang, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu, Tong Wang, Yan Yin, Yong Li, Anwen Liu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-10-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	pulmonary sarcomatoid carcinoma immune checkpoint inhibitors immunotherapy anlotinib camrelizumab tislelizumab
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.956982/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!